In the case of rare or chronic illnesses in particular, promising new therapies may be used outside the indication, or a new drug may not yet be available or not be approved in Switzerland. A commitment to cover costs is required if a medication is to be used outside the approved indication, otherwise reimbursement is not guaranteed. The same applies if a drug has not yet been approved. In such cases, MediService clarifies reimbursement issues with the responsible authorities (health insurance, prescribers and, if necessary, pharmaceutical companies) in advance and then enables the purchase of the medication. This provides access to new therapies for patients who would otherwise have no further alternative.